About Timber Pharmaceuticals
Timber Pharmaceuticals is a Healthcare company based in Woodcliff Lake (United States) founded in 2011, and was acquired by LEO Pharma in August 2023. Therapeutics for dermatological rare diseases are developed. The company has 5 employees. Its chief executive, as recorded, is John Koconis. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is BIOPHARMX CORP. Its competitors include Revance Therapeutics, Dermavant and Sol-Gel Technologies; 3 of its 3 listed competitors have raised funding.
Company details
Timber Pharmaceuticalsdevelops drugs for the dermatoological rare diseases. The leading candidate PAT-001 will begin its phase 2B study for Congenital Ichthyosis as claimed by the company in 2019. Its proprietary IPEG delivery system optimizes API delivery from affected skin layers hence helps in minimizing systemic absorption and removing irritating excipients.
- Headquarters Woodcliff Lake, United States
- Employees 5
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website timberpharma.com
- Social LinkedIn
- Acquired by LEO Pharma (Aug 2023)
- Legal Name Biopharmx Corp
- Annual Revenue$83.18 K (USD)-91as on Dec 31, 2022
- Latest Funding Round$25M (USD), Post-IPO
Mar 2020
- InvestorsLEO Pharma
& 1 more
- Employee Count5
- Acquired byLEO Pharma
(Aug 2023)
Funding Insights of Timber Pharmaceuticals
- Total Rounds 2
- Last Round Post-IPO — $25M
- First Round $1.62M
(Sep 2018)
- Investors Count 1
All 2 funding rounds of Timber Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $25M | Post-IPO | – | – | – |
| Sep 2018 | $1.62M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Timber Pharmaceuticals
Timber Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include LEO Pharma and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of drugs for treating dermatology diseases | 1908 | leo-pharma.com | Copenhagen, Denmark |
Investor details for Timber Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Timber Pharmaceuticals
3 people are tracked at Timber Pharmaceuticals (1 in leadership, 2 in board & advisors); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
John Koconis | CEO & Chairman | Leadership |
Edward Sitar | Director | Board & advisors |
David Cohen | Director | Board & advisors |
Complete people profiles for Timber Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Timber Pharmaceuticals
5 dated milestones of Timber Pharmaceuticals across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Timber Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.6M.
- Funding Latest funding round, Post-IPO, of $25.0M.
- Exit Acquired by LEO Pharma.
Competitors of Timber Pharmaceuticals
Timber Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Dermavant and Sol-Gel Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. | ||
| sol-gel.com | 1998 | United States | $9M | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. |
Detailed competitors of Timber Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Timber Pharmaceuticals (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Timber Pharmaceuticals
Complete news archive for Timber Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Timber Pharmaceuticals
Timber Pharmaceuticals was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Timber Pharmaceuticals is headquartered in Woodcliff Lake, United States. It is registered at Woodcliff Lake, New Jersey, United States.
John Koconis is the CEO of Timber Pharmaceuticals, as recorded in our data.
Timber Pharmaceuticals has 5 employees.
Annual revenue of Timber Pharmaceuticals is $83.18K as on Dec 31, 2022.
Timber Pharmaceuticalsdevelops drugs for the dermatoological rare diseases. The leading candidate PAT-001 will begin its phase 2B study for Congenital Ichthyosis as claimed by the company in 2019. Its proprietary IPEG delivery system optimizes API delivery from affected skin layers hence helps in minimizing systemic absorption and removing irritating excipients.
Timber Pharmaceuticals's top competitors include Revance Therapeutics, Dermavant and Sol-Gel Technologies.
Timber Pharmaceuticals has 2 investors. Key investors include LEO Pharma, and HHS.
Timber Pharmaceuticals operates through Biopharmx Corp.
Yes. Timber Pharmaceuticals was acquired by LEO Pharma in August 2023.